Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 299

1.

Improved CNS Control of Childhood Acute Lymphoblastic Leukemia Without Cranial Irradiation: St Jude Total Therapy Study 16.

Jeha S, Pei D, Choi J, Cheng C, Sandlund JT, Coustan-Smith E, Campana D, Inaba H, Rubnitz JE, Ribeiro RC, Gruber TA, Raimondi SC, Khan RB, Yang JJ, Mullighan CG, Downing JR, Evans WE, Relling MV, Pui CH.

J Clin Oncol. 2019 Oct 28:JCO1901692. doi: 10.1200/JCO.19.01692. [Epub ahead of print]

PMID:
31657981
2.

Pathologic Features of Down Syndrome Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Report From the Children's Oncology Group Protocol AAML0431.

Mast KJ, Taub JW, Alonzo TA, Gamis AS, Mosse CA, Mathew P, Berman JN, Wang YC, Jones HM, Campana D, Coustan-Smith E, Raimondi SC, Hirsch B, Hitzler JK, Head DR.

Arch Pathol Lab Med. 2019 Aug 20. doi: 10.5858/arpa.2018-0526-OA. [Epub ahead of print]

PMID:
31429606
3.

Masked hypodiploidy: Hypodiploid acute lymphoblastic leukemia (ALL) mimicking hyperdiploid ALL in children: A report from the Children's Oncology Group.

Carroll AJ, Shago M, Mikhail FM, Raimondi SC, Hirsch BA, Loh ML, Raetz EA, Borowitz MJ, Wood BL, Maloney KW, Mattano LA Jr, Larsen EC, Gastier-Foster J, Stonerock E, Ell D, Kahwash S, Devidas M, Harvey RC, Chen IL, Willman CL, Hunger SP, Winick NJ, Carroll WL, Rao KW, Heerema NA.

Cancer Genet. 2019 Oct;238:62-68. doi: 10.1016/j.cancergen.2019.07.009. Epub 2019 Jul 30.

PMID:
31425927
4.

Treatment response and outcome of children with T-cell acute lymphoblastic leukemia expressing the gamma-delta T-cell receptor.

Pui CH, Pei D, Cheng C, Tomchuck SL, Evans SN, Inaba H, Jeha S, Raimondi SC, Choi JK, Thomas PG, Dallas MH.

Oncoimmunology. 2019 May 17;8(8):1599637. doi: 10.1080/2162402X.2019.1599637. eCollection 2019.

PMID:
31413907
5.

Deciphering the Significance of CD56 Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Pardo LM, Voigt AP, Alonzo TA, Wilson ER, Gerbing RB, Paine DJ, Dai F, Menssen AJ, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Wells DA, Brodersen LE, Loken MR.

Cytometry B Clin Cytom. 2019 Jul 11. doi: 10.1002/cyto.b.21829. [Epub ahead of print]

PMID:
31294507
6.

Clofarabine Can Replace Anthracyclines and Etoposide in Remission Induction Therapy for Childhood Acute Myeloid Leukemia: The AML08 Multicenter, Randomized Phase III Trial.

Rubnitz JE, Lacayo NJ, Inaba H, Heym K, Ribeiro RC, Taub J, McNeer J, Degar B, Schiff D, Yeoh AE, Coustan-Smith E, Wang L, Triplett B, Raimondi SC, Klco J, Choi J, Pounds S, Pui CH.

J Clin Oncol. 2019 Aug 10;37(23):2072-2081. doi: 10.1200/JCO.19.00327. Epub 2019 Jun 27.

PMID:
31246522
7.

Functional Properties of KIT Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia.

Tarlock K, Alonzo TA, Wang YC, Gerbing RB, Ries R, Loken MR, Pardo L, Hylkema T, Joaquin J, Sarukkai L, Raimondi SC, Hirsch B, Sung L, Aplenc R, Bernstein I, Gamis AS, Meshinchi S, Pollard JA.

Clin Cancer Res. 2019 Aug 15;25(16):5038-5048. doi: 10.1158/1078-0432.CCR-18-1897. Epub 2019 Jun 10.

PMID:
31182436
8.

Chromosome arm 1q gain is an adverse prognostic factor in localized and diffuse leptomeningeal glioneuronal tumors with BRAF gene fusion and 1p deletion.

Chiang J, Dalton J, Upadhyaya SA, Patay Z, Qaddoumi I, Li X, Segura AD, Sharma S, Ismail A, Shurtleff SA, Raimondi SC.

Acta Neuropathol. 2019 Jan;137(1):179-181. doi: 10.1007/s00401-018-1940-x. Epub 2018 Nov 21. No abstract available.

PMID:
30465258
9.

Correction: Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.

Lamba JK, Cao X, Raimondi SC, Rafiee R, Downing JR, Shi L, Gruber T, Ribeiro RC, Rubnitz JE, Pounds SB.

Oncotarget. 2018 Jul 13;9(54):30473. doi: 10.18632/oncotarget.25792. eCollection 2018 Jul 13.

10.

Integrated epigenetic and genetic analysis identifies markers of prognostic significance in pediatric acute myeloid leukemia.

Lamba JK, Cao X, Raimondi SC, Rafiee R, Downing JR, Lei S, Gruber T, Ribeiro RC, Rubnitz JE, Pounds SB.

Oncotarget. 2018 Jun 1;9(42):26711-26723. doi: 10.18632/oncotarget.25475. eCollection 2018 Jun 1. Erratum in: Oncotarget. 2018 Jul 13;9(54):30473.

11.

Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma.

Broniscer A, Jia S, Mandrell B, Hamideh D, Huang J, Onar-Thomas A, Gajjar A, Raimondi SC, Tatevossian RG, Stewart CF.

Pediatr Blood Cancer. 2018 Jul;65(7):e27035. doi: 10.1002/pbc.27035. Epub 2018 Mar 7.

12.

γδ T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Discussion of Two Pediatric Cases and Its Distinction from Other Mature γδ T-Cell Malignancies.

Wei EX, Leventaki V, Choi JK, Raimondi SC, Azzato EM, Shurtleff SA, Ong MG, Veillon DM, Cotelingam JD, Shackelford RE.

Case Rep Hematol. 2017;2017:5873015. doi: 10.1155/2017/5873015. Epub 2017 Sep 24.

13.

Phenotype in combination with genotype improves outcome prediction in acute myeloid leukemia: a report from Children's Oncology Group protocol AAML0531.

Voigt AP, Brodersen LE, Alonzo TA, Gerbing RB, Menssen AJ, Wilson ER, Kahwash S, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Wells DA, Loken MR.

Haematologica. 2017 Dec;102(12):2058-2068. doi: 10.3324/haematol.2017.169029. Epub 2017 Sep 7.

14.

Arsenic Trioxide Consolidation Allows Anthracycline Dose Reduction for Pediatric Patients With Acute Promyelocytic Leukemia: Report From the Children's Oncology Group Phase III Historically Controlled Trial AAML0631.

Kutny MA, Alonzo TA, Gerbing RB, Wang YC, Raimondi SC, Hirsch BA, Fu CH, Meshinchi S, Gamis AS, Feusner JH, Gregory JJ Jr.

J Clin Oncol. 2017 Sep 10;35(26):3021-3029. doi: 10.1200/JCO.2016.71.6183. Epub 2017 Aug 2.

15.

Gemtuzumab ozogamicin in infants with AML: results from the Children's Oncology Group trials AAML03P1 and AAML0531.

Guest EM, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Alonzo TA, Gerbing RB, Wang YJ, Kahwash SB, Heerema-McKenney A, Meshinchi S, Gamis AS.

Blood. 2017 Aug 17;130(7):943-945. doi: 10.1182/blood-2017-01-762336. Epub 2017 Jul 3. No abstract available.

16.

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.

Lamba JK, Chauhan L, Shin M, Loken MR, Pollard JA, Wang YC, Ries RE, Aplenc R, Hirsch BA, Raimondi SC, Walter RB, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S.

J Clin Oncol. 2017 Aug 10;35(23):2674-2682. doi: 10.1200/JCO.2016.71.2513. Epub 2017 Jun 23.

17.

Germline SAMD9 mutation in siblings with monosomy 7 and myelodysplastic syndrome.

Schwartz JR, Wang S, Ma J, Lamprecht T, Walsh M, Song G, Raimondi SC, Wu G, Walsh MF, McGee RB, Kesserwan C, Nichols KE, Cauff BE, Ribeiro RC, Wlodarski M, Klco JM.

Leukemia. 2017 Aug;31(8):1827-1830. doi: 10.1038/leu.2017.142. Epub 2017 May 10. No abstract available.

18.

Disease Characteristics and Prognostic Implications of Cell-Surface FLT3 Receptor (CD135) Expression in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Tarlock K, Alonzo TA, Loken MR, Gerbing RB, Ries RE, Aplenc R, Sung L, Raimondi SC, Hirsch BA, Kahwash SB, McKenney A, Kolb EA, Gamis AS, Meshinchi S.

Clin Cancer Res. 2017 Jul 15;23(14):3649-3656. doi: 10.1158/1078-0432.CCR-16-2353. Epub 2017 Jan 20.

19.

Erratum to: High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB.

J Hematol Oncol. 2016 Nov 30;9(1):133. No abstract available.

20.

Deregulation of DUX4 and ERG in acute lymphoblastic leukemia.

Zhang J, McCastlain K, Yoshihara H, Xu B, Chang Y, Churchman ML, Wu G, Li Y, Wei L, Iacobucci I, Liu Y, Qu C, Wen J, Edmonson M, Payne-Turner D, Kaufmann KB, Takayanagi SI, Wienholds E, Waanders E, Ntziachristos P, Bakogianni S, Wang J, Aifantis I, Roberts KG, Ma J, Song G, Easton J, Mulder HL, Chen X, Newman S, Ma X, Rusch M, Gupta P, Boggs K, Vadodaria B, Dalton J, Liu Y, Valentine ML, Ding L, Lu C, Fulton RS, Fulton L, Tabib Y, Ochoa K, Devidas M, Pei D, Cheng C, Yang J, Evans WE, Relling MV, Pui CH, Jeha S, Harvey RC, Chen IL, Willman CL, Marcucci G, Bloomfield CD, Kohlschmidt J, Mrózek K, Paietta E, Tallman MS, Stock W, Foster MC, Racevskis J, Rowe JM, Luger S, Kornblau SM, Shurtleff SA, Raimondi SC, Mardis ER, Wilson RK, Dick JE, Hunger SP, Loh ML, Downing JR, Mullighan CG; St. Jude Children's Research Hospital–Washington University Pediatric Cancer Genome Project.

Nat Genet. 2016 Dec;48(12):1481-1489. doi: 10.1038/ng.3691. Epub 2016 Oct 24.

21.

miR-155 expression and correlation with clinical outcome in pediatric AML: A report from Children's Oncology Group.

Ramamurthy R, Hughes M, Morris V, Bolouri H, Gerbing RB, Wang YC, Loken MR, Raimondi SC, Hirsch BA, Gamis AS, Oehler VG, Alonzo TA, Meshinchi S.

Pediatr Blood Cancer. 2016 Dec;63(12):2096-2103. doi: 10.1002/pbc.26157. Epub 2016 Aug 11.

22.

Clinical impact of minimal residual disease in children with different subtypes of acute lymphoblastic leukemia treated with Response-Adapted therapy.

Pui CH, Pei D, Raimondi SC, Coustan-Smith E, Jeha S, Cheng C, Bowman WP, Sandlund JT, Ribeiro RC, Rubnitz JE, Inaba H, Gruber TA, Leung WH, Yang JJ, Downing JR, Evans WE, Relling MV, Campana D.

Leukemia. 2017 Feb;31(2):333-339. doi: 10.1038/leu.2016.234. Epub 2016 Aug 18.

23.

CD33 Expression and Its Association With Gemtuzumab Ozogamicin Response: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531.

Pollard JA, Loken M, Gerbing RB, Raimondi SC, Hirsch BA, Aplenc R, Bernstein ID, Gamis AS, Alonzo TA, Meshinchi S.

J Clin Oncol. 2016 Mar 1;34(7):747-55. doi: 10.1200/JCO.2015.62.6846. Epub 2016 Jan 19.

24.

Gemtuzumab Ozogamicin Reduces Relapse Risk in FLT3/ITD Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Tarlock K, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Sung L, Pollard JA, Aplenc R, Loken MR, Gamis AS, Meshinchi S.

Clin Cancer Res. 2016 Apr 15;22(8):1951-7. doi: 10.1158/1078-0432.CCR-15-1349. Epub 2015 Dec 7.

25.

Outcome of children with hypodiploid ALL treated with risk-directed therapy based on MRD levels.

Mullighan CG, Jeha S, Pei D, Payne-Turner D, Coustan-Smith E, Roberts KG, Waanders E, Choi JK, Ma X, Raimondi SC, Fan Y, Yang W, Song G, Yang JJ, Inaba H, Downing JR, Leung WH, Bowman WP, Relling MV, Evans WE, Zhang J, Campana D, Pui CH.

Blood. 2015 Dec 24;126(26):2896-9. doi: 10.1182/blood-2015-09-671131. Epub 2015 Nov 2. No abstract available.

26.

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Kentsis A, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB.

J Hematol Oncol. 2015 Oct 20;8:115. doi: 10.1186/s13045-015-0215-4. Erratum in: J Hematol Oncol. 2016 Nov 30;9(1):133.

27.

Clinical significance of in vivo cytarabine-induced gene expression signature in AML.

Lamba JK, Pounds S, Cao X, Crews KR, Cogle CR, Bhise N, Raimondi SC, Downing JR, Baker SD, Ribeiro RC, Rubnitz JE.

Leuk Lymphoma. 2016;57(4):909-20. doi: 10.3109/10428194.2015.1086918. Epub 2015 Oct 16.

28.

Heterogeneous cytogenetic subgroups and outcomes in childhood acute megakaryoblastic leukemia: a retrospective international study.

Inaba H, Zhou Y, Abla O, Adachi S, Auvrignon A, Beverloo HB, de Bont E, Chang TT, Creutzig U, Dworzak M, Elitzur S, Fynn A, Forestier E, Hasle H, Liang DC, Lee V, Locatelli F, Masetti R, De Moerloose B, Reinhardt D, Rodriguez L, Van Roy N, Shen S, Taga T, Tomizawa D, Yeoh AE, Zimmermann M, Raimondi SC.

Blood. 2015 Sep 24;126(13):1575-84. doi: 10.1182/blood-2015-02-629204. Epub 2015 Jul 27.

29.

Ethnic variation of TET2 SNP rs2454206 and association with clinical outcome in childhood AML: a report from the Children's Oncology Group.

Kutny MA, Alonzo TA, Gamazon ER, Gerbing RB, Geraghty D, Lange B, Heerema NA, Sung L, Aplenc R, Franklin J, Raimondi SC, Hirsch BA, Konkashbaev A, Cox NJ, Onel K, Gamis AS, Meshinchi S.

Leukemia. 2015 Dec;29(12):2424-6. doi: 10.1038/leu.2015.171. Epub 2015 Jul 1. No abstract available.

30.

Multimerin-1 (MMRN1) as Novel Adverse Marker in Pediatric Acute Myeloid Leukemia: A Report from the Children's Oncology Group.

Laszlo GS, Alonzo TA, Gudgeon CJ, Harrington KH, Gerbing RB, Wang YC, Ries RE, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB.

Clin Cancer Res. 2015 Jul 15;21(14):3187-95. doi: 10.1158/1078-0432.CCR-14-2684. Epub 2015 Mar 30.

31.

SMARCB1 deletion by a complex three-way chromosomal translocation in an extrarenal malignant rhabdoid tumor.

Bahrami A, Lee S, Caradine KD, Raimondi SC, Folpe AL.

Cancer Genet. 2014 Sep;207(9):437-40. doi: 10.1016/j.cancergen.2014.08.002. Epub 2014 Aug 24.

PMID:
25312828
32.

Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy.

Karol SE, Coustan-Smith E, Cao X, Shurtleff SA, Raimondi SC, Choi JK, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D, Inaba H.

Br J Haematol. 2015 Jan;168(1):94-101. doi: 10.1111/bjh.13107. Epub 2014 Aug 28.

33.

NUP98/NSD1 and FLT3/ITD coexpression is more prevalent in younger AML patients and leads to induction failure: a COG and SWOG report.

Ostronoff F, Othus M, Gerbing RB, Loken MR, Raimondi SC, Hirsch BA, Lange BJ, Petersdorf S, Radich J, Appelbaum FR, Gamis AS, Alonzo TA, Meshinchi S.

Blood. 2014 Oct 9;124(15):2400-7. doi: 10.1182/blood-2014-04-570929. Epub 2014 Aug 21.

34.

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: results from the randomized phase III Children’s Oncology Group trial AAML0531.

Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC, Hirsch BA, Kahwash SB, Heerema-McKenney A, Winter L, Glick K, Davies SM, Byron P, Smith FO, Aplenc R.

J Clin Oncol. 2014 Sep 20;32(27):3021-32.

35.

Outcomes of children with BCR-ABL1–like acute lymphoblastic leukemia treated with risk-directed therapy based on the levels of minimal residual disease.

Roberts KG, Pei D, Campana D, Payne-Turner D, Li Y, Cheng C, Sandlund JT, Jeha S, Easton J, Becksfort J, Zhang J, Coustan-Smith E, Raimondi SC, Leung WH, Relling MV, Evans WE, Downing JR, Mullighan CG, Pui CH.

J Clin Oncol. 2014 Sep 20;32(27):3012-20.

36.

A revised definition for cure of childhood acute lymphoblastic leukemia.

Pui CH, Pei D, Campana D, Cheng C, Sandlund JT, Bowman WP, Hudson MM, Ribeiro RC, Raimondi SC, Jeha S, Howard SC, Bhojwani D, Inaba H, Rubnitz JE, Metzger ML, Gruber TA, Coustan-Smith E, Downing JR, Leung WH, Relling MV, Evans WE.

Leukemia. 2014 Dec;28(12):2336-43. doi: 10.1038/leu.2014.142. Epub 2014 Apr 30.

37.

Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children's Oncology Group.

Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS, Meshinchi S.

Br J Haematol. 2014 Jul;166(2):254-259. doi: 10.1111/bjh.12852. Epub 2014 Mar 25.

38.

High expression of suppressor of cytokine signaling-2 predicts poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Laszlo GS, Ries RE, Gudgeon CJ, Harrington KH, Alonzo TA, Gerbing RB, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S, Walter RB.

Leuk Lymphoma. 2014 Dec;55(12):2817-21. doi: 10.3109/10428194.2014.893305. Epub 2014 Mar 24.

39.

t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.

Sandahl JD, Coenen EA, Forestier E, Harbott J, Johansson B, Kerndrup G, Adachi S, Auvrignon A, Beverloo HB, Cayuela JM, Chilton L, Fornerod M, de Haas V, Harrison CJ, Inaba H, Kaspers GJ, Liang DC, Locatelli F, Masetti R, Perot C, Raimondi SC, Reinhardt K, Tomizawa D, von Neuhoff N, Zecca M, Zwaan CM, van den Heuvel-Eibrink MM, Hasle H.

Haematologica. 2014 May;99(5):865-72. doi: 10.3324/haematol.2013.098517. Epub 2014 Jan 17.

40.

Nasopharyngeal alveolar rhabdomyosarcoma expressing CD56: a mimicker of extranodal natural killer/T-cell lymphoma.

Win KT, Lee MY, Tan TD, Tsai MP, Bahrami A, Raimondi SC, Chuang SS.

Int J Clin Exp Pathol. 2013 Dec 15;7(1):451-5. eCollection 2014.

41.

An international study of intrachromosomal amplification of chromosome 21 (iAMP21): cytogenetic characterization and outcome.

Harrison CJ, Moorman AV, Schwab C, Carroll AJ, Raetz EA, Devidas M, Strehl S, Nebral K, Harbott J, Teigler-Schlegel A, Zimmerman M, Dastuge N, Baruchel A, Soulier J, Auclerc MF, Attarbaschi A, Mann G, Stark B, Cazzaniga G, Chilton L, Vandenberghe P, Forestier E, Haltrich I, Raimondi SC, Parihar M, Bourquin JP, Tchinda J, Haferlach C, Vora A, Hunger SP, Heerema NA, Haas OA; Ponte di Legno International Workshop in Childhood Acute Lymphoblastic Leukemia.

Leukemia. 2014 May;28(5):1015-21. doi: 10.1038/leu.2013.317. Epub 2013 Oct 29.

42.

BIRC5 (survivin) splice variant expression correlates with refractory disease and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

Moore AS, Alonzo TA, Gerbing RB, Lange BJ, Heerema NA, Franklin J, Raimondi SC, Hirsch BA, Gamis AS, Meshinchi S.

Pediatr Blood Cancer. 2014 Apr;61(4):647-52. doi: 10.1002/pbc.24822. Epub 2013 Oct 11.

43.

Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols: a report from the Children's Oncology Group.

Johnston DL, Alonzo TA, Gerbing RB, Hirsch B, Heerema NA, Ravindranath Y, Woods WG, Lange BJ, Gamis AS, Raimondi SC.

Pediatr Blood Cancer. 2013 Dec;60(12):2073-8. doi: 10.1002/pbc.24573. Epub 2013 Aug 30.

PMID:
24039149
44.

The prognostic effect of high diagnostic WT1 gene expression in pediatric AML depends on WT1 SNP rs16754 status: report from the Children's Oncology Group.

Ho PA, Alonzo TA, Gerbing RB, Kuhn J, Pollard JA, Hirsch B, Raimondi SC, Gamis AS, Meshinchi S.

Pediatr Blood Cancer. 2014 Jan;61(1):81-8. doi: 10.1002/pbc.24700. Epub 2013 Aug 16.

PMID:
23956224
45.

High EVI1 expression is associated with MLL rearrangements and predicts decreased survival in paediatric acute myeloid leukaemia: a report from the children's oncology group.

Ho PA, Alonzo TA, Gerbing RB, Pollard JA, Hirsch B, Raimondi SC, Cooper T, Gamis AS, Meshinchi S.

Br J Haematol. 2013 Sep;162(5):670-7. doi: 10.1111/bjh.12444. Epub 2013 Jul 4.

46.

Significance of expression of ITGA5 and its splice variants in acute myeloid leukemia: a report from the Children's Oncology Group.

Walter RB, Laszlo GS, Alonzo TA, Gerbing RB, Levy S, Fitzgibbon MP, Gudgeon CJ, Ries RE, Harrington KH, Raimondi SC, Hirsch BA, Gamis AS, W McIntosh M, Meshinchi S.

Am J Hematol. 2013 Aug;88(8):694-702. doi: 10.1002/ajh.23486. Epub 2013 Jun 20.

47.

Successful treatment of pediatric plasmacytoid dendritic cell tumors with a contemporary regimen for acute lymphoblastic leukemia.

Wright KD, Onciu MM, Coustan-Smith E, Campana D, Raimondi SC, Inaba H, Ribeiro R, Pui CH, Sandlund JT.

Pediatr Blood Cancer. 2013 Jul;60(7):E38-41. doi: 10.1002/pbc.24483. Epub 2013 Feb 15.

48.

The genomic landscape of hypodiploid acute lymphoblastic leukemia.

Holmfeldt L, Wei L, Diaz-Flores E, Walsh M, Zhang J, Ding L, Payne-Turner D, Churchman M, Andersson A, Chen SC, McCastlain K, Becksfort J, Ma J, Wu G, Patel SN, Heatley SL, Phillips LA, Song G, Easton J, Parker M, Chen X, Rusch M, Boggs K, Vadodaria B, Hedlund E, Drenberg C, Baker S, Pei D, Cheng C, Huether R, Lu C, Fulton RS, Fulton LL, Tabib Y, Dooling DJ, Ochoa K, Minden M, Lewis ID, To LB, Marlton P, Roberts AW, Raca G, Stock W, Neale G, Drexler HG, Dickins RA, Ellison DW, Shurtleff SA, Pui CH, Ribeiro RC, Devidas M, Carroll AJ, Heerema NA, Wood B, Borowitz MJ, Gastier-Foster JM, Raimondi SC, Mardis ER, Wilson RK, Downing JR, Hunger SP, Loh ML, Mullighan CG.

Nat Genet. 2013 Mar;45(3):242-52. doi: 10.1038/ng.2532. Epub 2013 Jan 20.

49.

Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia.

Inaba H, Coustan-Smith E, Cao X, Pounds SB, Shurtleff SA, Wang KY, Raimondi SC, Onciu M, Jacobsen J, Ribeiro RC, Dahl GV, Bowman WP, Taub JW, Degar B, Leung W, Downing JR, Pui CH, Rubnitz JE, Campana D.

J Clin Oncol. 2012 Oct 10;30(29):3625-32. doi: 10.1200/JCO.2011.41.5323. Epub 2012 Sep 10.

50.

Prognostic features in acute megakaryoblastic leukemia in children without Down syndrome: a report from the AML02 multicenter trial and the Children's Oncology Group Study POG 9421.

O'Brien MM, Cao X, Pounds S, Dahl GV, Raimondi SC, Lacayo NJ, Taub J, Chang M, Weinstein HJ, Ravindranath Y, Inaba H, Campana D, Pui CH, Rubnitz JE.

Leukemia. 2013 Mar;27(3):731-4. doi: 10.1038/leu.2012.223. Epub 2012 Aug 3. No abstract available.

Supplemental Content

Loading ...
Support Center